At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 

These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.

Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 

In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.

To learn more about the topics in this episode: 


Introducing Fierce Biotech's 2024 Fierce 15


Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline


Synthekine hopes new IL-2 will be the high-alpha in a beta class

At this year’s Fierce Biotech Summit in Boston, we caught up with leaders in the biotech industry who have been recognized as past Fierce 15 honorees. 
These private biotechs have made significant contributions to their field, and their groundbreaking work is shaping the industry's future.
Fierce Biotech’s Gabrielle Masson sat down with Liang Schweizer, Ph.D. founder, chairperson and CEO of HiFiBiO Therapeutics; Adam Friedman, M.D., Ph.D., CEO of Scorpion Therapeutics; and Debanjan Ray CEO of Synthekine. 
In this week’s episode of “The Top Line,” these leaders share their insights, experiences, and visions for the evolving biotech landscape.
To learn more about the topics in this episode: 
<ul>
<li>
<a href="https://www.fiercebiotech.com/special-reports/introducing-fierce-biotechs-2024-fierce-15">Introducing Fierce Biotech's 2024 Fierce 15</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/scorpion-snaps-150m-series-c-funds-widen-clinical-plans-cancer-pipeline">Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline</a>
</li>
<li>
<a href="https://www.fiercebiotech.com/biotech/aacr-synthekine-hopes-new-il-2-will-be-high-alpha-beta-class">Synthekine hopes new IL-2 will be the high-alpha in a beta class</a> 
</li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Where are they now? Catching up with past Fierce 15 honorees

 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images. 

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct.

To learn more about the topics in this episode:  

NIH neuroscience leader committed research misconduct, agency investigation finds

Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images. 
In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct.
To learn more about the topics in this episode:  
<a href="https://www.fiercebiotech.com/research/head-national-institute-aging-neuroscience-division-eliezer-masliah-found-have-committed">NIH neuroscience leader committed research misconduct, agency investigation finds</a>

Misconduct and the future of neurodegenerative disease research

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. 

In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.  

They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.  

To learn more about the topics in this episode: 
The 2024 Biotech Graveyard
Fierce Biotech Layoff Tracker 2024

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. 
In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.     They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/2024-biotech-graveyard">The 2024 Biotech Graveyard</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024">Fierce Biotech Layoff Tracker 2024</a></li>
</ul>

Dig into this year’s Fierce Biotech Graveyard, layoff numbers 

As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.  

While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.  

In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.  

To learn more about the topics in this episode: 
With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate
Biden touts drug pricing achievements as he steps down from reelection campaign
2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma

As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.  
While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.  
In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/us-voting-day-weeks-away-big-waves-pharma-front-are-unlikely-either-presidential-candidate">With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate</a></li>
<li><a href="https://www.fiercepharma.com/pharma/president-biden-steps-down-reelection-campaign-his-historic-drug-pricing-moves-remain">Biden touts drug pricing achievements as he steps down from reelection campaign</a></li>
<li><a href="https://www.fiercepharma.com/pharma/2024-forecast-recent-biden-administration-moves-show-theres-no-pricing-relief-industry">2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma</a></li>
</ul>

Where are they now? Catching up with past Fierce 15 honorees

The Top Line

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips